AIM: To elucidate anticancer effects of transcatheter arterial infusion chemotherapy (TAI) in @entity1 with @entity157 ( @entity157 ). METHODS: Data from a total of 95 @entity1 with @entity157 who received TAI were analyzed retrospectively. The efficacy of TAI was evaluated according to the Response Evaluation Criteria in @entity96 . Overall survival was calculated from the date of initial treatment to the date of @entity204 or last follow-up. Survival curves were calculated by the Kaplan-Meier method, and differences in survival were evaluated by the log rank test. Clinical variables that were identified as statistically different by a univariate analysis were included into the Cox proportional hazard regression model for multivariate analysis. A prognostic index based on the regression coefficients derived from variables identified by the multivariate analysis was constructed. Stratification of the @entity1 was conducted using this prognostic index. RESULTS: The @entity1 group was comprised of 76 @entity1 and 19 @entity1 with an average age of 68 years (range: 37-82 years). Six @entity1 (6.3%) showed complete response and 18 @entity1 (18.9%) showed partial response, for an overall response rate of 25.2%. The median overall survival was 27.6 mo, and the proportions of survivors at 1, 2, and 5 years were 67.4%, 54.0%, and 17.4%, respectively. Multivariate analysis demonstrated that no prior transcatheter arterial chemoembolization, @entity880 dehydrogenase < 230 IU/L, and performance status of 0 were the independent favorable prognostic factors. The development of a 0-3-point prognostic score index was based on the sum of these three prognostic factors. Subsequently, the @entity1 were categorized into three groups: those with a good (prognostic index = 0-1; n = 54), intermediate (prognostic index = 2; n = 26), or poor (prognostic index = 3; n = 15) prognosis. The median survival times in these three groups were 41.0, 21.2, and 6.8 mo, respectively (P < 0.01). CONCLUSION: Our simple prognostic index may be helpful for management of @entity1 in determining treatment strategies for advanced @entity157 in the era of molecularly targeted therapy.

Transcatheter arterial infusion for advanced XXXX : Who are candidates?

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient', 'men'] @entity96 :: ('MESH:D008113', 'Disease') :: ['Cancer of the Liver'] @entity880 :: ('MESH:D019344', 'Chemical') :: ['lactate'] @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'hepatocellular carcinoma'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death']
@entity157 :: (MESH:D006528,Disease) :: ['hepatocellular carcinoma']
